EP4731768A2 - Verabreichung von rna-therapeutika unter verwendung von ringförmigen nukleinsäuren - Google Patents

Verabreichung von rna-therapeutika unter verwendung von ringförmigen nukleinsäuren

Info

Publication number
EP4731768A2
EP4731768A2 EP24826715.5A EP24826715A EP4731768A2 EP 4731768 A2 EP4731768 A2 EP 4731768A2 EP 24826715 A EP24826715 A EP 24826715A EP 4731768 A2 EP4731768 A2 EP 4731768A2
Authority
EP
European Patent Office
Prior art keywords
oligonucleotide
nucleotides
modified
region
rso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24826715.5A
Other languages
English (en)
French (fr)
Inventor
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arnay Sciences LLC
Original Assignee
Arnay Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arnay Sciences LLC filed Critical Arnay Sciences LLC
Publication of EP4731768A2 publication Critical patent/EP4731768A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24826715.5A 2023-06-23 2024-06-21 Verabreichung von rna-therapeutika unter verwendung von ringförmigen nukleinsäuren Pending EP4731768A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363522878P 2023-06-23 2023-06-23
US202363524009P 2023-06-29 2023-06-29
PCT/US2024/034985 WO2024263891A2 (en) 2023-06-23 2024-06-21 Delivery of rna therapeutics using ring-shaped nucleic acids

Publications (1)

Publication Number Publication Date
EP4731768A2 true EP4731768A2 (de) 2026-04-29

Family

ID=93936278

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24826715.5A Pending EP4731768A2 (de) 2023-06-23 2024-06-21 Verabreichung von rna-therapeutika unter verwendung von ringförmigen nukleinsäuren

Country Status (11)

Country Link
EP (1) EP4731768A2 (de)
JP (1) JP2026521760A (de)
KR (1) KR20260030126A (de)
CN (1) CN121620594A (de)
AU (1) AU2024312646A1 (de)
CL (1) CL2025004036A1 (de)
CO (1) CO2026000616A2 (de)
IL (1) IL325432A (de)
JO (1) JOP20250321A1 (de)
MX (1) MX2025015413A (de)
WO (1) WO2024263891A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
KR20240082367A (ko) * 2021-09-23 2024-06-10 아르네이 사이언시스 엘엘씨 치료학적 물질로서 고리형 구조의 올리고뉴클레오티드

Also Published As

Publication number Publication date
MX2025015413A (es) 2026-05-04
WO2024263891A3 (en) 2025-04-03
JP2026521760A (ja) 2026-07-01
JOP20250321A1 (ar) 2025-12-21
KR20260030126A (ko) 2026-03-05
CL2025004036A1 (es) 2026-05-15
AU2024312646A1 (en) 2026-01-08
CO2026000616A2 (es) 2026-02-13
CN121620594A (zh) 2026-03-06
IL325432A (en) 2026-02-01
WO2024263891A2 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
CN109312338B (zh) 治疗单纯疱疹病毒的crispr/cas相关方法及组合物
EP2470656B1 (de) Zusammensetzung zur genexpressionshemmung und ihre anwendungen
JP2025071108A (ja) Ｒｎａがんワクチン
CA2528597C (en) Stabilized immunomodulatory oligonucleotides
JP2024009014A (ja) 血友病ａに対する遺伝子編集用組成物及び方法
US20250270550A1 (en) Cyclic Structured Oligonucleotides as Therapeutic Agents
US20260062703A1 (en) Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids
CN113728102A (zh) 使用剪接调节化合物进行新抗原工程化
WO2024263891A2 (en) Delivery of rna therapeutics using ring-shaped nucleic acids
AU2024316992A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
CA3207104A1 (en) Oligonucleotides
US20260078373A1 (en) Cyclic Antisense Therapeutics
JP7560544B2 (ja) 遺伝子スプライシングを調節するために有用な化合物および方法
HK40079272A (en) Compounds and methods useful for modulating gene splicing
HK40062073A (en) Neoantigen engineering using splice modulating compounds

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR